NAARDEN, Netherlands--(BUSINESS WIRE)--Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has received very positive results in its Phase 2b TULIP clinical trial, a double blind, placebo controlled, Phase 2b dose ranging study of TA-8995 (DEZ-001), as monotherapy and in combination with statins for treating dyslipidemia. The TULIP (“TA-8995: its Use in patients with mild dysLIPidemia”) study was conducted in specialized cardiovascular centres across Denmark and the Netherlands. A total of 364 patients were randomised into nine cohorts; a placebo, TA-8995 alone at different doses, or in combination with...
↧